期刊文献+

基于单中心的血管免疫母细胞性T细胞淋巴瘤的临床特征及预后分析 被引量:4

Clinical characteristics and prognosis of angioimmunoblastic T-cell lymphoma based on single clinical center
下载PDF
导出
摘要 目的:探讨血管免疫母细胞性T细胞淋巴瘤(angioimmunoblastic T-cell lymphoma, AITL)的临床特征及预后。方法:回顾性分析2005年11月至2017年6月复旦大学附属中山医院血液科收治的36例经病理及免疫组织化学确诊为AITL患者的临床资料。采用log-rank生存分析及Cox多因素分析法分析影响患者总生存期(overall survival, OS)的预后因素。结果:36例患者中位年龄62(36~79)岁,男性22例(61.1%),Ann Arbor分期Ⅲ/Ⅳ期35例(97.2%),有B症状(发热、盗汗、体质量减轻)25例(69.4%)。国际预后指数(international prognostic index, IPI)评分0~1分3例(8.3%),2分5例(13.9%),3分13例(36.1%),4、5分共15例(41.7%)。患者中位生存时间为24.4个月,3年OS率为49.2%。5例患者接受西达本胺治疗,1例为完全缓解(CR)后复发,经GemOx方案联合西达本胺治疗,再次获得CR;另4例均为一线治疗过程中出现疾病进展(PD),二线治疗的同时联合西达本胺口服,其中1例出现疾病稳定(SD),3例死亡。单因素生存分析结果显示,多浆膜腔积液(P=0.05)、C反应蛋白(CRP)>40 mg/L(P=0.001)、中性粒细胞升高(P=0.004)是影响患者OS的不良因素。多因素分析结果显示,CRP>40 mg/L[(HR=9.185,95%置信区间(CI) 2.599~32.462,P=0.001]、血小板(PLT)<150×10~9/L(HR=3.851,95%CI 1.328~11.167,P=0.013)、多浆膜腔积液(HR=3.054,95%CI 1.105~8.438,P=0.031)是影响患者OS的独立不良预后因素。结论:AITL患者预后差,CRP>40 mg/L、PLT<150×10~9/L、多浆膜腔积液是其独立风险因素。 Objective:To explore the clinical characteristics and prognostic factors of patients with angioimmunoblastic T-cell lymphoma (AITL).Methods: The clinical characteristics and prognostic factors of 36 patients with AITL were retrospectively analyzed, all of whom were treated at the Department of Hematology, Zhongshan Hospital, Fudan University between November 2005 and June 2017, and were confirmed by pathology and immunohistochemistry. Log-rank survival analysis and Cox multivariate analysis were used to analyze the prognostic factors affecting the overall survival (OS) of patients. Results: The median age of 36 patients was 62 (36-79) years old, with 61.1% males ( n =22), 97.2% Ann Arbor stage Ⅲ/Ⅳ( n =35), and 69.4% with B symptoms ( n =25). Three cases (8.3%) were categorized as 0-1, 5 cases (13.9%) as 2, 13 cases (36.1%) as 3, and 15 cases (41.7%) as 4 and 5 for the international prognostic index (IPI). The median survival time was 24.4 months, and the 3-year OS rate was 49.2%. Five cases were treated with chidamide, one of whom had relapse after complete remission (CR), after GemOx combined with chidamide treatment, reached CR again. The other 4 cases had disease progression (PD) during the first-line treatment. They were treated with chidamide as a part of the second-line treatment. Among whom, 1 case had stable disease (SD) and 3 cases died. Univariate survival analysis showed that multiple serous effusion ( P =0.05), CRP >40 mg/L ( P =0.001), and neutrophil >7×10 9/L ( P =0.004) were the adverse prognostic factors affecting OS. Multivariate analysis showed that CRP >40 mg/L (HR=9.185, 95% CI 2.599-32.462, P =0.001), PLT <150×10 9/L (HR=3.851, 95% CI 1.328-11.167, P =0.013), multiple serous effusion (HR= 3.054, 95% CI 1.105-8.438, P =0.031) were independent prognostic factors for OS. Conclusions: The prognosis of AITL is poor. CRP>40 mg/L, PLT<150×10 9/L, and multiple serous effusion might be independent adverse prognostic factors for OS.
作者 张雪皎 季丽莉 王伟光 程志祥 袁玲 魏征 承璐雅 柯杨 庄静丽 王志梅 李锋 邹善华 刘澎 ZHANG Xue-jiao;JI Li-li;WANG Wei-guang;CHENG Zhi-xiang;YUAN Ling;WEI Zheng;CHENG Lu-ya;KE Yang;ZHUANG Jing-li;WANG Zhi-mei;LI Feng;ZOU Shan-hua;LIU Peng(Department of Hematology, Zhongshan Hospital, Fudan University, Shanghai 200032, China)
出处 《中国临床医学》 2019年第1期1-5,共5页 Chinese Journal of Clinical Medicine
基金 国家自然科学基金(81570123) 上海市卫生系统优秀学科带头人计划(2017BR033)~~
关键词 血管免疫母细胞性T细胞淋巴瘤 多浆膜腔积液 西达本胺 预后 angioimmunoblastic T-cell lymphoma multiple serous effusion chidamide prognosis
  • 相关文献

参考文献1

二级参考文献3

共引文献4

同被引文献9

引证文献4

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部